Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 trial of LB-001 for the treatment of methylmalonic acidemia (MMA)

Trial Profile

Phase 1/2 trial of LB-001 for the treatment of methylmalonic acidemia (MMA)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LB 001 (Primary)
  • Indications Methylmalonic acidaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors LogicBio Therapeutics
  • Most Recent Events

    • 16 Mar 2020 According to a LogicBio Therapeutics media release, the company expects to have interactions with the FDA regarding their questions through mid-2020, after which we plan to provide guidance on the anticipated timing for the initiation of this trial
    • 10 Feb 2020 According to a LogicBio Therapeutics media release, U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions. The company expects that the FDA questions will be provided in writing in 30 days. The company plans to work closely with the FDA to resolve these questions as quickly as possible.
    • 10 Jan 2020 According to a LogicBio Therapeutics media release, company has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate this study.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top